Genematrix Inc
KOSDAQ:109820
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
G
|
Genematrix Inc
KOSDAQ:109820
|
48B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
406.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
71.4B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Genematrix Inc
Glance View
GENEMATRIX, Inc. engages in the development of platform and molecular diagnostics products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 60 full-time employees. The company went IPO on 2009-11-06. The firm operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Genematrix Inc is 60.7%, which is above its 3-year median of 53.5%.
Over the last 3 years, Genematrix Inc’s Gross Margin has increased from 49.4% to 60.7%. During this period, it reached a low of 46.8% on Mar 31, 2023 and a high of 60.7% on Jun 30, 2025.
